Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7411 to 7425 of 7687 results

  1. Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]

    Discontinued [GID-TA10750]

    Technology appraisal guidance
    Discontinued

  2. Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]

    In development [GID-TA10758] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]

    In development [GID-TA11089] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]

    In development [GID-TA11166] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007

    In development [GID-TA11567] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)

    This guidance has been updated and replaced by NICE technology appraisal guidance 988.

    Technology appraisal guidance
    Published
    27 July 2016

  7. Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer [ID6461]

    In development [GID-TA11580] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. The MAGEC system for spinal lengthening in children with scoliosis (MTG18)

    August 2024: Following the lifting on the UK suspension of MAGEC system (modified MAGEC X system), NICE's prioritisation board will be reviewing the guidance that was withdrawn in April 2020. We will update this page once a decision is made.

    Medical technologies guidance
    Published
    18 June 2014

  9. Peezy Midstream for urine collection (MIB183)

    NICE has withdrawn the med tech innovation briefing (MIB) on Peezy Midstream for urine collection because there is published evidence that shows it offers no clinical benefits over standard care (clean catch method).

    Medtech innovation briefing
    Published
    8 May 2019

  10. Peezy Midstream for urine collection (MT446)

    In development [GID-MT538] Expected publication date: TBC

    Medical technologies guidance
    In development

  11. Microstructural scaffold (patch) insertion without autologous cell implantation for repairing symptomatic chondral knee defects (IPG560)

    This guidance has been updated and replaced by NICE interventional procedures guidance 793.

    Interventional procedures guidance
    Published
    22 June 2016

  12. Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial cancer [ID6417]

    Discontinued [GID-TA11522]

    Technology appraisal guidance
    Discontinued

  13. Common mental health problems: identification and pathways to care (CG123)

    We withdrew this guideline in May 2024, because all of the recommendations are now covered in other NICE guidelines, or are out of date and no longer relevant to clinical practice. For guidance on common mental health problems, see our guidelines on:

    Clinical guideline
    Published
    25 May 2011

  14. Intrapartum care for healthy women and babies - rectal examination after delivery

    Discontinued [GID-NG10395]

    NICE guideline
    Discontinued

  15. Violence and aggression: short-term management in mental health, health and community settings

    Discontinued [GID-NG10397]

    NICE guideline
    Discontinued